Fluvoxamine Delivers Measurable Relief From Long COVID Fatigue in Rigorous 399-Person Trial

In a field starved for answers, a 399-person randomized clinical trial has delivered something rare: a specific drug, tested rigorously, showing measurable relief for one of long COVID's most disabling symptoms. Fluvoxamine — an SSRI antidepressant that has been generic and inexpensive for years — significantly reduced fatigue and improved quality of life compared to placebo. That's not a trend or a promising signal. That's a controlled trial outcome. What makes this finding particularly significant is what fluvoxamine already is: widely available, well-understood, and cheap. Millions of people suffering from long COVID fatigue don't need to wait for a novel compound to clear regulatory pipelines. The therapeutic candidate exists today, on pharmacy shelves, at a price that doesn't require insurance negotiations or pharmaceutical assistance programs. Long COVID fatigue is not ordinary tiredness. Clinicians describe it as post-exertional malaise — a crushing, sometimes weeks-long crash triggered by even mild physical or cognitive effort. Patients have lost jobs, relationships, and years of their lives to it. The absence of effective treatments has been one of medicine's more urgent open wounds since 2020. A drug that moves the needle on this, even partially, represents a genuine shift in what clinicians can offer. The trial's design — randomized, placebo-controlled, involving nearly 400 participants — meets the evidentiary standard that separates signal from noise. Researchers will rightly call for replication and larger studies, as good science demands. But for the estimated tens of millions worldwide still carrying the burden of long COVID, this is the kind of specific, sourced, data-backed development that earns the word hope.